Daehan New Pharm is leveraging its Uzbekistan export of key products, including Lution, to expand into the CIS region. For overseas buyers and distributors, this signals growing access to injectable and wellness products in Central Asia, with the company actively seeking new partners and attending trade shows.
Uzbekistan as a CIS export hub
Daehan New Pharm has registered Lution and other major products with Uzbek authorities and is now exporting injectables to the country. The company's Q1 report lists CIS, the Middle East, and South America as target regions for overseas sales expansion, with Uzbekistan emerging as a key gateway to neighboring CIS markets.
Regulatory advantage drives Uzbekistan choice
A company representative told Medipana News that registering Korean pharmaceuticals in Uzbekistan is relatively easier than in other CIS countries, even though procedures have become slightly stricter recently. This regulatory environment has made Uzbekistan a strategic base for the company's CIS expansion.
Injectable focus aligns with wellness trend
The Uzbekistan export is centered on injectable products, reflecting confirmed local demand. This matches Daehan New Pharm's stated strategy to expand vitamin injectables and wellness products, which the company noted in its Q1 report are growing as a share of revenue.
New plant to support export growth
Daehan New Pharm is building a new injectable production line at its Hyangnam plant, targeting startup in early next year. The facility is intended to scale up export volumes and meet rising demand from Uzbekistan and potentially other CIS markets.
What buyers should watch
Distributors and clinics in CIS and Central Asia should monitor Daehan New Pharm's product registration progress in Uzbekistan and neighboring countries. The company's focus on injectables and wellness products, combined with new production capacity, may offer sourcing opportunities for medical aesthetics and clinic consumables.
Source: Read the original report | Published: June 11, 2026